By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn (CYDY)’s Phase IIb Monotherapy Extension Study Now Available 6/22/2016 7:43:22 AM
CytoDyn (CYDY)n’s PRO 140 Phase IIb HIV Monotherapy Trial Findings To Be Presented At ASM Microbe 2016 Conference On June 20 6/17/2016 8:08:47 AM
CytoDyn (CYDY) To Present At LD Micro Invitational Conference On June 7 6/2/2016 10:27:21 AM
Investors Aren't Impressed as Charlie Sheen Reveals He Wants in on Tiny CytoDyn (CYDY)'s HIV Drug Trial 2/12/2016 6:26:40 AM
CytoDyn Release: Uncontrolled Viral Loads: Experienced Patients Face Dwindling Pool Of Effective Options 1/28/2016 9:55:05 AM
CytoDyn Reports HIV-Patients Approaching 17 Months Of Complete Viral Suppression With PRO 140 Monotherapy 1/19/2016 10:31:52 AM
CytoDyn Release: Fighting GvHD And HIV At Same Time; Approval Of New Medical Discovery Expected In 2017 12/4/2015 2:29:52 PM
CytoDyn Release: Eleven HIV Patients Successfully Reach One Year Of Full Virologic Suppression In Pro 140 Monotherapy Phase IIb Extension Study 12/1/2015 7:27:05 AM
CytoDyn Hires New Senior Vice President Of Manufacturing For PRO 140 11/24/2015 8:18:02 AM
CytoDyn Announces Investment Community Conference Call 11/18/2015 7:30:54 AM